The recently completed NCT01872442 trial dealt with effectiveness and safety of dasatinib in combination with low dosage of Peg-IFNα2b as first line treatment for newly diagnosed chronic phase (CP) CML patients. This evidence concerns the gene IFNA2 and chronic myelogenous leukemia, BCR-ABL1 positive.